Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pacritinib · 1 trial · 3 indications
Evaluate clinical efficacy of pacritinib and selinexor in myelofibrosis patients who are JAK inhibitor-naïve and have anemia and thrombocytopenia by assessing spleen volume reduction (SVR) of 35% or greater compared to baseline as measured by imaging (MRI/CT)
| Arm | Type | Description |
|---|---|---|
| Pacritinib/Selinexor | EXPERIMENTAL | Study participants will receive pacritinib monotherapy (200mg BID orally) for the first cycle (28 days). If they qualify to add on selinexor at any point from Cycle 2 Day 1 to Cycle 4 Day 1, participants will have selinexor (60mg QW orally) added onto their pacritinib regimen. |
| Name | Type | Description |
|---|---|---|
| Pacritinib | DRUG | Pacritinib 200mg twice a day (BID) by mouth (PO) |
| Selinexor | DRUG | Selinexor 60mg once weekly (QW) by mouth (PO) |
Inclusion Criteria: * Adults ≥ 18 years of age capable of providing informed consent * Pathologically confirmed diagnosis of PMF, post-ET MF, or post-PV MF as per the World Health Organization (WHO) diagnostic criteria - Intermediate-1, Intermediate-2, or High-Risk disease by the Dynamic Internatio...
Pacritinib is an investigational small molecule being studied for the treatment of myelofibrosis, including post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It is currently in Phase 2 clinical development for this indication.
Pacritinib is a kinase inhibitor, belonging to the -tinib class of drugs. It works by inhibiting certain kinases, which are enzymes involved in cell signaling and growth. This mechanism is being explored as a potential treatment for myelofibrosis.
Pacritinib is being developed by Karyopharm Therapeutics Inc., a biopharmaceutical company. Karyopharm is listed on the stock exchange under the ticker symbol KPTI.
Pacritinib is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. It is being studied in a clinical trial for patients with myelofibrosis.
Pacritinib is being studied in a Phase 2 clinical trial with the identifier NCT07447817. This trial is investigating the combination of selinexor and pacritinib in JAK inhibitor-naive patients with myelofibrosis who have cytopenias. The trial is not yet recruiting and plans to enroll 26 participants in the United States.
No, Pacritinib is not the same as selinexor. They are different drugs being studied in combination in a clinical trial for myelofibrosis. Pacritinib is a kinase inhibitor, while selinexor is a separate investigational agent. The trial NCT07447817 is evaluating both drugs together.